Arbutus Biopharma Reacquires Rights to Imdusiran in China-March 2024-www.financetom.com

Arbutus Biopharma Reacquires Rights to Imdusiran in China

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Arbutus Biopharma Reacquires Rights to Imdusiran in China

Jun 25, 2025 5:38 AM

08:08 AM EDT, 06/25/2025 (MT Newswires) -- Arbutus Biopharma ( ABUS ) said Wednesday that it has reacquired rights to its lead compound, imdusiran, in Greater China from Qilu Pharmaceutical.

Arbutus said the parties have mutually agreed to end their partnership, which began in 2021, to develop, manufacture and commercialize imdusiran in mainland China and other Asian markets.

Previous page： Davos-Musk expects European approval for Tesla's Full Self-Driving system by next month Next page： Spice Giant McCormick Stumbles, CEO Blames Inflation, Tariffs

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Davos-Musk expects European approval for Tesla's Full Self-Driving system by next month

Mar 11, 2026

Jan 22 (Reuters) - Elon ‌Musk said on ‍Thursday ⁠he ⁠expects Tesla ‌to receive ⁠European ‍approval for its Full Self-Driving ‍advanced driver assistance ‍system by next month. (Reporting by Akash Sriram in ‍Bengaluru) ...

Spice Giant McCormick Stumbles, CEO Blames Inflation, Tariffs

Mar 11, 2026

McCormick & Company, Incorporated ( MKC ) stock fell Thursday after the spice maker posted a mixed quarter. The company beat revenue expectations, but weaker profit performance and margin pressure weighed on sentiment. The company reported fourth-quarter adjusted earnings per share of 86 cents, missing the Street view of 88 cents. Quarterly sales of $1.850 billion outpaced the analyst consensus...

Spice Giant McCormick Stumbles, CEO Blames Inflation, Tariffs

Mar 11, 2026

Greenwich LifeSciences Stock Jumps After FDA Update

Mar 11, 2026

Greenwich LifeSciences, Inc. ( GLSI ) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial. Greenwich LifeSciences ( GLSI ) stock is among today’s top performers. What’s driving GLSI stock higher? FDA Clears First Commercial GP2 Lot for Phase III...